Compass Ion Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Compass Ion Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$484K	Sell	3,786 -100	-3%	-$12.5K	0.05%	182
2025 Q4	$474K	Buy	3,886 +97	+3%	+$11.1K	0.05%	182
2025 Q3	$380K	Buy	3,789 +62	+2%	+$5.58K	0.04%	203
2025 Q2	$309K	Buy	3,727 +140	+4%	+$11.2K	0.03%	209
2025 Q1	$291K	Sell	3,587 -247	-6%	-$22.1K	0.03%	211
2024 Q4	$345K	Hold	3,834	–	–	0.04%	198
2024 Q3	$379K	Buy	3,834 +2	+0.1%	+$197	0.05%	190
2024 Q2	$364K	Hold	3,832	–	–	0.05%	166
2024 Q1	$364K	Buy	3,832 +441	+13%	+$40.9K	0.05%	165
2023 Q4	$303K	Hold	3,391	–	–	0.05%	186
2023 Q3	$248K	Buy	+3,391	New	+$271K	0.04%	202

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Compass Ion Advisors's XBI Position: Q1 2026 in Review

Compass Ion Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2.6% in Q1 2026, selling an estimated $12.5K and leaving 3,786 shares worth $484K. The position accounts for 0.05% of the portfolio, ranked #182.

Compass Ion Advisors first reported a position in XBI in Q3 2023 and has held it in 11 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Compass Ion Advisors held 3,786 shares of State Street SPDR S&P Biotech ETF worth $484K as of Q1 2026.
Compass Ion Advisors sold 100 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $12.5K.
State Street SPDR S&P Biotech ETF made up 0.05% of Compass Ion Advisors's portfolio in Q1 2026, its #182 holding.
Compass Ion Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and has held it in 11 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Compass Ion Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.